URUrology Research3083-49102981-8230Bio-Byword Scientific Publishing Pty. Ltd.10.26689/ur.v3i3.12366ArticleEfficacy and Safety of Firsekibart in Gout Patients with Different Estimated Glomerular Filtration Rateshttps://artdesignp.com/journal/UR/3/3/10.26689/ur.v3i3.12366XueYu,LiYi,LianYuling,GuFei,ChenChunxia,XuQian2025332025-10-23To compare the efficacy and safety of Firsekibart versus compound betamethasone in gout patients with different estimated glomerular filtration rate (eGFR) levels. Methods: Patients were randomized, double blinded and separated into two equal groups to receive a single dose of Firsekibart (200 mg) or compound betamethasone (7 mg). Patients were divided into three subgroups according to baseline eGFR: ≥ 90, 60–89, and 30–59 mL/min/1.73 m² to evaluate 72-hour pain relief, 12/24-week recurrence rate, renal function changes, and safety events. Results: Of 311 patients in full analysis set (FAS), 113 (36.3%) had baseline eGFR 60–89 mL/min/1.73 m2, and 42 (13.5%) had baseline eGFR 30–59 mL/min/1.73 m2. Similar reduction in visual analogue scale (VAS) scores at 72-hour was observed in each eGFR subgroup between Firsekibart and compound betamethasone group (p > 0.05). Compared with compound betamethasone, Firsekibart reduced the risk of recurrence at 12/24 weeks in patients with different eGFR subgroups (all p < 0.0001). In safety evaluation, no obvious changes of creatinine and eGFR were observed in each subgroup during 24-week follow up. Treatment emergent adverse events (TEAEs) incidence was comparable in each eGFR subgroup analysis. In total, 1 (0.6%) patient experienced emergent serious adverse events (TESAE) and 0 treatment-related adverse events (TRSAE) was reported in the Firsekibart group compared to 6 (3.8%) and 3 (1.9%) in the compound betamethasone group, respectively. Conclusion: Overall, Firsekibart demonstrated non-inferior short-term pain relief while offering better prevention of new flares, with a lower incidence of serious adverse events compared to compound betamethasone, and results were consistent across eGFR subgroups. Both Firsekibart and compound betamethasone showed little effect on renal function.

Wang X, Luo D, Ru Y, et al., 2021, Guidelines for Hyperuricemia and Gout from the Perspective of Chronic Kidney Disease. Chinese Journal of General Practice, 24(33): 4191–4195.

Dehlin M, Jacobsson L, Roddy E, 2020, Global Epidemiology of Gout: Prevalence, Incidence, Treatment Patterns and Risk Factors. Nature Reviews Rheumatology, 16(7): 380–390.

Zhu Y, Pandya B, Choi H, 2012, Comorbidities of Gout and Hyperuricemia in the US General Population: NHANES 2007–2008. American Journal of Medicine, 125(7): 679–687.

Lee T, Chen J, Wu C, et al., 2021, Hyperuricemia and Progression of Chronic Kidney Disease: A Review from Physiology and Pathogenesis to the Role of Urate-Lowering Therapy. Diagnostics, 11(9): 1674.

Xu D, Zhu X, Zou H, et al., 2023, Gout Diagnosis and Treatment Standards. Chinese Journal of Internal Medicine, 62(09): 1068–1076.

Pofi R, Caratti G, Ray D, et al., 2023, Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good from the Bad? Endocrine Reviews, 44(6): 975–1011.

Dumusc A, So A, 2015, Interleukin-1 as a Therapeutic Target in Gout. Current Opinion in Rheumatology, 27(2): 156–163.

Loustau C, Rosine N, Forien M, et al., 2018, Effectiveness and Safety of Anakinra in Gout Patients with Stage 4–5 Chronic Kidney Disease or Kidney Transplantation: A Multicentre, Retrospective Study. Joint Bone Spine, 85(6): 755–760.

Schlesinger N, Pillinger M, Simon L, et al., 2023, Interleukin-1β Inhibitors for the Management of Acute Gout Flares: A Systematic Literature Review. Arthritis Research & Therapy, 25(1): 128.

Schlesinger N, 2014, Anti-Interleukin-1 Therapy in the Management of Gout. Current Rheumatology Reports, 16(2): 398.

Speer T, Dimmeler S, Schunk S, et al., 2022, Targeting Innate Immunity-Driven Inflammation in CKD and Cardiovascular Disease. Nature Reviews Nephrology, 18(12): 762–778.

Liu Y, Lei H, Zhang W, et al., 2023, Pyroptosis in Renal Inflammation and Fibrosis: Current Knowledge and Clinical Significance. Cell Death & Disease, 14(7): 472.

Xue Y, Chu T, Hu J, et al., 2025, Firsekibart in Acute Gouty Arthritis. Journal of Translational Medicine, 23(1): 91.

Neogi T, Jansen T, Dalbeth N, et al., 2015, Gout Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Annals of the Rheumatic Diseases, 74(10): 1789–1798.

Chapter 2: Definition, Identification, and Prediction of CKD Progression, 2013, Kidney International Supplements, 3(1): 63–72.

Cipolletta E, Tata L, Nakafero G, et al., 2022, Association Between Gout Flare and Subsequent Cardiovascular Events Among Patients with Gout. JAMA, 328(5): 440–450.

Bardin T, Nguyen Q, Tran K, et al., 2021, A Cross-Sectional Study of 502 Patients Found a Diffuse Hyperechoic Kidney Medulla Pattern in Patients with Severe Gout. Kidney International, 99(1): 218–226.

Stamp L, Farquhar H, Pisaniello H, et al., 2021, Management of Gout in Chronic Kidney Disease: A G-CAN Consensus Statement on the Research Priorities. Nature Reviews Rheumatology, 17(10): 633–641.

Im P, Kartsonaki C, Kakkoura M, et al., 2025, Hyperuricemia, Gout and the Associated Comorbidities in China: Findings from a Prospective Study of 0.5 million Adults. Lancet Regional Health – Western Pacific, 58: 101572.

KDIGO, 2024, Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International, 105(4): S117–S314.

Munar M, Singh H, 2007, Drug Dosing Adjustments in Patients with Chronic Kidney Disease. American Family Physician, 75(10): 1487–1496.

Busso N, So A, 2010, Mechanisms of Inflammation in Gout. Arthritis Research & Therapy, 12(2): 206.

Schreiber A, Pham C, Hu Y, et al., 2012, Neutrophil Serine Proteases Promote IL-1β Generation and Injury in Necrotizing Crescentic Glomerulonephritis. Journal of the American Society of Nephrology, 23(3): 470–482.

Shi Y, 2010, Caught Red-Handed: Uric Acid is an Agent of Inflammation. Journal of Clinical Investigation, 120(6): 1809–1811.

Ponticelli C, Podesta M, Moroni G, 2020, Hyperuricemia as a Trigger of Immune Response in Hypertension and Chronic Kidney Disease. Kidney International, 98(5): 1149–1159.